Maryland Primary Care Program
August 2021 – 3rd COVID-19 Vaccine Dose for Immunocompromised Patients: Guide for Primary Care Practices
On August 12, the FDA amended the emergency use authorizations (EUAs) for both the Pfizer and Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals. CDC followed by recommending a 3rd dose of mRNA vaccine for these individuals with moderate to severe immune compromise. Read More
Potential CMMI Policy Changes Affecting MDPCP
CMMI has informed the Maryland Department of Health that MDPCP would no longer be considered an Advanced Alternate Payment Model beginning in Calendar Year (CY) 2022. This designation has been an important incentive for practices to participate in the program, allowing them to receive a 5% lump sum payment based on Medicare fee-for-service and to be exempted from having to participate in the Merit-based Incentive Payment System (MIPS). Read More
Thank you for your continued effort to support the holistic needs of Maryland patients. To those of you who have implemented the evidence-based approach of SBIRT to address substance use including the ongoing opioid epidemic, we want to acknowledge your commitment to being part of the solution.
MDPCP is a major part of the 10-year contract with CMS known as the “Maryland Model.” In this Model the State has made a bold and important commitment to improving the health of Marylanders. Let me provide an update on one of those goals. Under Milestone 3 of the Statewide Integrated Health Improvement Strategy (SIHIS), the MDPCP has committed to expanding SBIRT implementation into primary care practices, with a goal of implementing SBIRT in 200 practices by the end of 2021. In order to meet this milestone, MDPCP will continue to offer free consulting services for SBIRT implementation through June 2021. If you are interested in learning more, please reach out to your MDPCP coach or Erin Cosgrove at Mosaic (firstname.lastname@example.org).
The State also requests that MDPCP practices performing SBIRT report monthly data via CRISP on the number of screenings, brief interventions, and referrals performed. Monthly reporting (by the 5th of the month) will allow the opportunity to identify areas of opportunity and need at the practice and state level. To minimize burden, the State is establishing an easy to use reporting site on the CRISP Unified Landing Page (ULP). You will be notified when the site is available later this spring. The site will ask for the same data as the template elements that Mosaic set up with each practice. The State acknowledges that additional reporting may be a burden to some practices and will make every effort to simplify and automate this process.
We appreciate your commitment to meeting our state’s population health goals and improving care for all Marylanders.
CMMI has released a list of practices that have been accepted into the program. Please view the full list to confirm your practice’s status.
Accepted practices should have already received a series of emails from CMMI regarding next steps and onboarding materials. If you do not see your practice ID listed, you should assume your practice site’s application has been deferred for 2019 program participation. Deferred practices will receive a letter from CMMI in mid-December confirming their deferral status and a brief acknowledgment of why their application did not meet requirements. In early 2019, the State will reach out and engage with deferred practices regarding how to prepare to re-apply for upcoming Performance Years. For further questions about your application, please reach out to CMS at MarylandModel@cms.hhs.gov.
Accepted practices should have received several email communications from CMMI detailing next steps. Practices should check their spam folders and make sure MarylandModel@cms.hhs.gov is added to their safe senders list. Please keep an eye on your inbox for important emails regarding the specific items below.
For a detailed overview of upcoming program milestones, please see our updated timeline.